The Alive Study: A Longitudinal Study of HIV-1 Infection in Intravenous Drug Users: Description of Methods

To identify risk factors for infection with the human immunodeficiency virus (HIV) and for progression to the acquired immunodeficiency syndrome (AIDS) among intravenous drug users, we established a cohort in Baltimore Maryland in 1988–1989. Intravenous drug users were recruited by extensive community outreach to undergo interview and confidential HIV testing in a special study site. During 13 months of recruitment, 2,921 intravenous drug users were enrolled of whome 24 percent were HIV seropositive; 90 percent returned to receive test results. Methodological issues for enhancing recruitment and retention of drug users are discussed.

[1]  Ccfp,et al.  The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells. , 1985, Canadian Medical Association journal.

[2]  Joan S. Chmiel,et al.  Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. , 1989, American journal of epidemiology.

[3]  S Magura,et al.  Determinants of needle sharing among intravenous drug users. , 1989, American journal of public health.

[4]  R. Hoffman,et al.  Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Biernacki,et al.  TARGETED SAMPLING: OPTIONS FOR THE STUDY OF HIDDEN POPULATIONS , 1989 .

[6]  S. Zolla-Pazner,et al.  Kaposi's sarcoma among four different AIDS risk groups. , 1984, The New England journal of medicine.

[7]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[8]  J. Phair,et al.  Predictors of decline in CD4 lymphocytes in a cohort of homosexual men infected with human immunodeficiency virus. , 1988, Journal of acquired immune deficiency syndromes.

[9]  W. El-Sadr,et al.  Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. , 1987, AIDS.

[10]  D. Shine,et al.  Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. , 1985, Archives of internal medicine.

[11]  S. Friedman,et al.  Prevalence of antibody to lymphadenopathy-associated virus among drug-detoxification patients in New York. , 1984, The New England journal of medicine.

[12]  J. Garber,et al.  Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users. , 1987, AIDS.

[13]  W. El-Sadr,et al.  The epidemic of acquired immunodeficiency syndrome (AIDS) and suggestions for its control in drug abusers. , 1984, Journal of substance abuse treatment.

[14]  S. Zolla-Pazner,et al.  Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[15]  B. Truman,et al.  Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. , 1987, The New England journal of medicine.

[16]  M. Chamberland,et al.  Heterosexually acquired infection with human immunodeficiency virus (HIV). A view from the III International Conference on AIDS. , 1987, Annals of internal medicine.

[17]  J. Levy,et al.  Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. , 1987, JAMA.

[18]  J. Jaffe,et al.  Geographic distribution of human immunodeficiency virus markers in parenteral drug abusers. , 1988, American journal of public health.

[19]  R. Chaisson,et al.  Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. , 1987, American journal of public health.